» Articles » PMID: 11959812

A Possible Role for Insulin-like Growth Factor-binding Protein-3 Autocrine/paracrine Loops in Controlling Hepatocellular Carcinoma Cell Proliferation

Overview
Date 2002 Apr 18
PMID 11959812
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is a common malignancy, but treatment outcomes have generally remained poor. Specific factors important for the pathogenesis of HCC are incompletely understood. Insulin-like growth factors (IGFs) are potent autocrine and paracrine mitogens for liver cancer cell proliferation, and their bioactivity is reduced by IGF-binding protein 3 (IGFBP-3). In the present study, we report that IGFBP-3 protein levels were either undetectable (28.5%) or low (71.5%) in human HCC samples examined compared with matched non-neoplastic liver tissue by Western blotting. IGFBP-3 was localized to nontumor liver cells by immunohistochemistry with greater immunointensity than neoplastic liver cells. Levels of type I receptor (IGF-IR) were found to be low in approximately 39% of human HCC samples examined compared with matched nontumor tissues. IGF-II was overexpressed in 32%, whereas IGF-I expression was decreased in 100% of HCC samples. In vitro studies revealed that IGF-I and IGF-II induced HepG2 cell proliferation in a dose-dependent manner. Treatment of HepG2 cells with either human recombinant IGFBP-3 (hrIGFBP-3) or IGF-II antibody led to a significant reduction in cell proliferation. Cotreating these cells with hrIGFBP-3 significantly attenuated the mitogenic activity of IGF-I. IGF-I-induced phosphorylation of IGF-IR beta subunit, IRS-1, mitogen-activated protein kinase, Elk-1, and Akt-1 as well as phosphatidylinositol 3'-kinase activity was significantly attenuated when hepG2 cells were pretreated with hrIGFBP-3. Our data indicate that loss of autocrine/paracrine IGFBP-3 loops may lead to HCC tumor growth and suggest that modulating production of the IGFs, IGFBP-3, and IGF-IR may represent a novel approach in the treatment of HCC.

Citing Articles

Construction and validation of a novel IGFBP3-related signature to predict prognosis and therapeutic decision making for Hepatocellular Carcinoma.

Chen J, Zhuang W, Xia Y, Yin X, Tu M, Zhang Y PeerJ. 2023; 11:e15554.

PMID: 37397026 PMC: 10312159. DOI: 10.7717/peerj.15554.


Down-regulation of hepatic expression of GHR/STAT5/IGF-1 signaling pathway fosters development and aggressiveness of HCV-related hepatocellular carcinoma: Crosstalk with Snail-1 and type 2 transforming growth factor-beta receptor.

Abu El-Makarem M, Kamel M, Mohamed A, Ali H, Mohamed M, Mohamed A PLoS One. 2022; 17(11):e0277266.

PMID: 36374927 PMC: 9662744. DOI: 10.1371/journal.pone.0277266.


Human amniotic mesenchymal stem cells inhibit hepatocellular carcinoma in tumour-bearing mice.

Liu Q, Li J, Zhang X, Liu Y, Liu Q, Xiao L J Cell Mol Med. 2020; 24(18):10525-10541.

PMID: 32798252 PMC: 7521292. DOI: 10.1111/jcmm.15668.


Loss of alanine-glyoxylate and serine-pyruvate aminotransferase expression accelerated the progression of hepatocellular carcinoma and predicted poor prognosis.

Sun Y, Li W, Shen S, Yang X, Lu B, Zhang X J Transl Med. 2019; 17(1):390.

PMID: 31771612 PMC: 6880547. DOI: 10.1186/s12967-019-02138-5.


Insulin-Like Growth Factor (IGF) System in Liver Diseases.

Adamek A, Kasprzak A Int J Mol Sci. 2018; 19(5).

PMID: 29702590 PMC: 5983723. DOI: 10.3390/ijms19051308.